OS Therapies Incorporated (OSTX)
ASE · Healthcare · Biotechnology
$1.48
-1.33%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$65.9M
Shares Outstanding
44.5M
Exchange
ASE
Currency
USD
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.8M | -6.9M | -12.0M | -10.2M |
| Net Income | -4.5M | -6.9M | -13.5M | -10.4M |
| Diluted EPS | $-0.19 | $-0.21 | $nan | $-0.27 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.4M | -4.3M | -6.8M | -28.7M |
| Net Income | -6.3M | -7.8M | -8.9M | -28.8M |
| Diluted EPS | $-0.32 | $-0.38 | $-1.28 | $-0.98 |